Here are the 10-K annual reports from NexGel, Inc (NXGL) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow NXGL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NXGL filings page.
NexGel, Inc. filed Amendment No. 1 to its annual report to add detailed Part III disclosures on directors, executive compensation, ownership, related-party transactions and auditor fees, without changing previously reported financial statements. The filing highlights a new CFO employment agreement, updated board committee roles, equity incentives and insider trading and clawback policies.
NexGel, Inc. reports strong top-line growth but continued losses in its annual report. Revenue for the year ended December 31, 2025 rose to $11.4 million, up 31.5% from 2024, driven mainly by expansion of branded consumer products including MedaGel, Kenkoderm and Silly George. Gross profit improved to $4.5 million, or 39.5% of revenue, but selling, general and administrative expenses increased to $7.9 million, reflecting higher compensation, marketing and professional fees. Research and development spending was minimal at $2 thousand as medical device projects focus on partnering and licensing rather than in-house commercialization. NexGel ended 2025 with $317 thousand in cash, $741 thousand in restricted cash and working capital of $1.4 million, and acknowledges substantial doubt about its ability to continue as a going concern without additional capital. The company highlights unused manufacturing capacity, a hydrogel contract manufacturing base, growing consumer brands and early-stage medical devices, while outlining extensive business, competitive, regulatory, supply chain, capital-raising and Nasdaq listing risks.